Inventor · disambiguated record
Gita Camilla Tejlgaard Kampen
Also filed as: KAMPEN GITA · KAMPEN GITA CAMILLA T · KAMPEN GITA CAMILLA TEJLGAARD
9 granted patents·13 pending applications·206 citations·filing 2005–2018
90Inventor score
Files withHIGH POINT PHARMACEUTICALS LLC8NOVO NORDISK AS5KILBURN JOHN PAUL4ZEALAND PHARMA AS2ANDERSEN HENRIK SUNE1
Top patents by PatentIndex Score
22 records- 0197US7501405B2Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disordersHIGH POINT PHARMACEUTICALS LLC·Filed 2005·Granted Mar 10, 2009·55 cites·3 claims
- 0293US7723323B2Pharmaceutical use of fused 1,2,4-triazolesHIGH POINT PHARMACEUTICALS LLC·Filed 2008·Granted May 25, 2010·32 cites·14 claims
- 0393US7358238B2Pharmaceutical use of fused 1,2,4-triazolesNOVO NORDISK AS·Filed 2005·Granted Apr 15, 2008·36 cites·9 claims
- 0491US10004786B2Acylated glucagon analoguesZEALAND PHARMA AS·Filed 2015·Granted Jun 26, 2018·12 cites·2 claims
- 0591US9156901B2Acylated glucagon analoguesRIBER DITTE·Filed 2010·Granted Oct 13, 2015·26 cites·14 claims
- 0690US7700583B211β-hydroxysteroid dehydrogenase type 1 active compoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2005·Granted Apr 20, 2010·30 cites·17 claims
- 0786US8053431B2Pharmaceutical use of substituted amidesHIGH POINT PHARMACEUTICALS LLC·Filed 2006·Granted Nov 8, 2011·9 cites·8 claims
- 0876US8153798B2Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitorsKILBURN JOHN PAUL·Filed 2007·Granted Apr 10, 2012·3 cites·4 claims
- 0976US8138342B211β-hydroxysteroid dehydrogenase type 1 active spiro compoundsKILBURN JOHN PAUL·Filed 2005·Granted Mar 20, 2012·3 cites·2 claims
- 1071US2009264412A1Combination Therapy Using An 11beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor And A Glucocorticoid Receptor Agonist To Minimize The Side Effects Associated With Glucocorticoid Receptor Agonist TherapyHIGH POINT PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 1166US2010120743A111Beta-Hydroxysteroid Dehydrogenase Type 1 Active CompoundsHIGH POINT PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 1262US2008108598A1Pharmaceutical use of substituted amidesNOVO NORDISK AS·Filed 2008·Application pending·0 cites
- 1360US2006094699A1Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapyKAMPEN GITA CAMILLA T·Filed 2005·Application pending·0 cites
- 1459US2009137574A1Combination Therapy Using an 11Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor and an Antihypertensive Agent for the Treatment of Metabolic Syndrome and Related Diseases and DisordersNOVO NORDISK AS·Filed 2009·Application pending·0 cites
- 1556US2006111366A1Pharmaceutical use of substituted amidesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
- 1655US2019076506A1Acylated glucagon analoguesZEALAND PHARMA AS·Filed 2018·Application pending·0 cites
- 1751US2009264414A1Amide Derivatives and Pharmaceutical Use ThereofHIGH POINT PHARMACEUTICALS LLC·Filed 2009·Application pending·0 cites
- 1847US2010197658A1Pharmaceutical use of fused 1,2,4-triazolesHIGH POINT PHARMACEUTICALS LLC·Filed 2010·Application pending·0 cites
- 1944US2009306048A1Pharmaceutical use of substituted piperidine carboxamidesKILBURN JOHN PAUL·Filed 2007·Application pending·0 cites
- 2044US2009124598A1Pharmaceutical use of substituted amidesANDERSEN HENRIK SUNE·Filed 2006·Application pending·0 cites
- 2144US2011312949A1Pharmaceutical use of substituted amidesKILBURN JOHN PAUL·Filed 2011·Application pending·0 cites
- 2241US2007270408A1Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidinesNOVO NORDISK AS·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gita Camilla Tejlgaard Kampen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →